Literature DB >> 1605590

Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.

V Joly1, J Bolard, L Saint-Julien, C Carbon, P Yeni.   

Abstract

We studied the influence of the lipid/amphotericin B (AMB) ratio and the phospholipid type on the in vitro renal cell toxicity and antifungal efficacy of lipid-associated AMB (L-AMB). L-AMB was prepared at one of two different lipid/AMB ratios (1 and 40) by incubating AMB with empty small unilamellar vesicles, made from one of three different phospholipids: dipalmitoyl-, dimirystoyl-, and distearoylphosphatidylcholine (DPPC, DMPC, and DSPC, respectively). Renal cell toxicity, investigated through an assessment of the Na-dependent uptake of phosphate by proximal tubular cells, and fungicidal effect against Candida albicans were studied after 1 h of treatment at 37 degrees C. The amount of unbound AMB present in each L-AMB formulation was studied by use of circular dichroism. At a lipid/AMB ratio of 40, the three lipidic formulations were not toxic for renal cells but were less effective against C. albicans than AMB; however, DSPC-AMB, which contained 50% unbound AMB, was more effective against C. albicans than DPCC-AMB or DMPC-AMB, containing 0 and 13% unbound AMB, respectively. At a lipid/AMB ratio of 1, the antifungal effects of L-AMB and AMB were similar, whatever the phospholipid used, but only DMPC-AMB remained highly protective against AMB renal cell toxicity, despite the presence of the same amount of unbound AMB (50%) in DMPC-AMB and DPPC-AMB. We conclude that the in vitro activities and renal cell toxicities of different L-AMB formulations are influenced by the phospholipid type and the lipid/AMB ratio. The optimal ratio depends on the phospholipid itself. At a lipid/AMB ratio of 40, the antifungal activity depends mainly on the amount of unbound AMB in the formulation. At a lipid/AMB ratio of 1, the renal cell toxicity also depends on the fluidity of the phospholipid.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605590      PMCID: PMC188347          DOI: 10.1128/AAC.36.2.262

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture.

Authors:  V Joly; L Saint-Julien; C Carbon; P Yeni
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

3.  Unusual lipid structures selectively reduce the toxicity of amphotericin B.

Authors:  A S Janoff; L T Boni; M C Popescu; S R Minchey; P R Cullis; T D Madden; T Taraschi; S M Gruner; E Shyamsunder; M W Tate
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

4.  Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures.

Authors:  H J Krause; R L Juliano
Journal:  Mol Pharmacol       Date:  1988-09       Impact factor: 4.436

5.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; L S Frankel; K Mehta
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

6.  Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.

Authors:  R L Juliano; C W Grant; K R Barber; M A Kalp
Journal:  Mol Pharmacol       Date:  1987-01       Impact factor: 4.436

7.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

8.  Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections.

Authors:  J P Sculier; A Coune; F Meunier; C Brassinne; C Laduron; C Hollaert; N Collette; C Heymans; J Klastersky
Journal:  Eur J Cancer Clin Oncol       Date:  1988-03

9.  Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits.

Authors:  V Joly; F Dromer; J Barge; P Yeni; N Seta; G Molas; C Carbon
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

10.  Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids.

Authors:  S Jullien; A Contrepois; J E Sligh; Y Domart; P Yeni; J Brajtburg; G Medoff; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  7 in total

Review 1.  In vitro models for studying toxicity of antifungal agents.

Authors:  V Joly; J Bolard; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 2.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.

Authors:  V Joly; R Farinotti; L Saint-Julien; M Chéron; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Evidence for the formation of amphotericin B-phospholipid complexes in Langmuir monolayers.

Authors:  M R Lance; C Washington; S S Davis
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 6.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

7.  Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.

Authors:  P Y Chavanet; I Garry; N Charlier; D Caillot; J P Kisterman; M D'Athis; H Portier
Journal:  BMJ       Date:  1992-10-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.